- Home
- JAGX vs NDRA Comparison
JAGX vs NDRA Comparison
Compare JAGX & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- NDRA
- Stock Information
- Founded
- JAGX 2013
- NDRA 2007
- Country
- JAGX United States
- NDRA United States
- Employees
- JAGX N/A
- NDRA N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- JAGX Health Care
- NDRA Health Care
- Exchange
- JAGX Nasdaq
- NDRA Nasdaq
- Market Cap
- JAGX 3.9M
- NDRA 3.9M
- IPO Year
- JAGX N/A
- NDRA 2017
- Fundamental
- Price
- JAGX $2.12
- NDRA $7.00
- Analyst Decision
- JAGX Strong Buy
- NDRA Strong Buy
- Analyst Count
- JAGX 1
- NDRA 1
- Target Price
- JAGX $60.00
- NDRA $38.00
- AVG Volume (30 Days)
- JAGX 227.5K
- NDRA 750.0K
- Earning Date
- JAGX 11-12-2025
- NDRA 11-14-2025
- Dividend Yield
- JAGX N/A
- NDRA N/A
- EPS Growth
- JAGX N/A
- NDRA N/A
- EPS
- JAGX N/A
- NDRA N/A
- Revenue
- JAGX $11,810,000.00
- NDRA N/A
- Revenue This Year
- JAGX $22.41
- NDRA N/A
- Revenue Next Year
- JAGX $30.00
- NDRA N/A
- P/E Ratio
- JAGX N/A
- NDRA N/A
- Revenue Growth
- JAGX 15.96
- NDRA N/A
- 52 Week Low
- JAGX $1.57
- NDRA $2.90
- 52 Week High
- JAGX $33.25
- NDRA $22.68
- Technical
- Relative Strength Index (RSI)
- JAGX 50.22
- NDRA 62.82
- Support Level
- JAGX $1.93
- NDRA $6.94
- Resistance Level
- JAGX $2.40
- NDRA $8.00
- Average True Range (ATR)
- JAGX 0.20
- NDRA 0.70
- MACD
- JAGX 0.00
- NDRA 0.14
- Stochastic Oscillator
- JAGX 36.28
- NDRA 39.52
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.